LIFE Launches Auto Imaging System - Analyst Blog
2013年7月17日 - 7:05AM
Zacks
Global biotechnology tool company Life Technologies
Corporation (LIFE) recently launched its auto imaging
system EVOS FL along with an on-stage incubator. Currently, any lab
can access this system. This system enables high-resolution longer
live automatic cell imaging for fluorescence microscopy and
time-lapse imaging on single integrated platform.
In spite of advanced features, Life Technologies claims this
system to be easy to operate and cheaper than its substitute
instruments in the market. Thus, with the commercialization,
adoptability of this EVOS FL is going to be high in the market.
Life Technologies enjoys a strong position in the life sciences
market. We are optimistic about the company’s focus on its
diagnostics franchise, which holds potential. Given the continuous
focus on portfolio expansion, we are confident about Life
Technologies garnering higher revenues from genetic analysis going
forward.
In Feb 2013, a dozen new products for the Ion Torrent platform
were launched based on advancing clinical research across the
world. These new products enabled Ion Torrent semiconductor
sequencing technology to expand 1,000-fold in just two years and
gain a 60% market share of benchtop sequencers. The company is also
positive about its Ion AmpliSeq Exome Kit which delivers industry’s
best exome sequencing performance, with higher exome coverage.
We also note Life Technologies’ efforts to expand its footprint
in high-growth markets through partnerships, acquisitions and
product innovation.
Following the disclosure of its acquisition by Thermo
Fisher Scientific Inc. (TMO), Life sharpened focus on its
product platform. We believe that the buyout, which is expected to
close in early 2014, will leverage Life’s attractive revenue
profile.
Given Life’s expansive line of consumables for genomic, and
molecular and cell biology, the takeover will complement Thermo
Fisher’s market-leading portfolio of analytical technologies and
specialty diagnostics.
However, Life Technologies carries a Zacks Rank #4 (Sell). Some
better performing medical stocks include Tornier
N.V. (TRNX) and Lannett Company, Inc.
(LCI) with a Zacks Rank #1 (Strong Buy).
LANNETT INC (LCI): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
THERMO FISHER (TMO): Free Stock Analysis Report
TORNIER NV (TRNX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
London Clubs (AMEX:LCI)
過去 株価チャート
から 6 2024 まで 7 2024
London Clubs (AMEX:LCI)
過去 株価チャート
から 7 2023 まで 7 2024